Travere Therapeutics stock forecast
Travere Therapeutics (17R) Stock Forecast & Price Target
17R Analyst Ratings
17R Stock 12 Month Forecast
Average Price Target
€66.06▲(100.19% Upside)Detailed List of Analyst Forecasts​
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Allison Bratzel | Piper Sandler | €61.69 | buy | 86.95%Upside | Reiterated | 11/16/26 | ||
| Anupam Rama | J.P. Morgan | €81.65→€78.02 | buy | 136.43%Upside | Reiterated | 11/06/26 | ||
| Leerink Partners | €70.77→€60.79 | buy | 84.20%Upside | Reiterated | 11/05/26 | |||
| Edward Nash | Canaccord Genuity | €63.51→€65.32 | buy | 97.95%Upside | Reiterated | 11/04/26 | ||
| Joseph Pantginis | H.C. Wainwright | €60.79 | buy | 84.20%Upside | Reiterated | 11/03/26 | ||
| Mohit Bansal | Wells Fargo | €72.58 | buy | 119.94%Upside | Assigned | 11/03/26 | ||
| Prakhar Agrawal | Cantor Fitzgerald | ― | buy | ― | Reiterated | 11/03/26 | ||
| Laura Chico | Wedbush | €68.95 | buy | 108.94%Upside | Reiterated | 11/03/26 | ||
| Alex Thompson CFA | Stifel Nicolaus | €56.25 | hold | 70.45%Upside | Reiterated | 11/03/26 | ||
| Jason Zemansky | Bank of America Securities | €64.41→€63.51 | buy | 92.45%Upside | Reiterated | 11/03/26 | ||
| Vamil Divan | Guggenheim | €80.75→€70.77 | buy | 114.44%Upside | Reiterated | 11/03/26 | ||
| Tyler Van Buren | TD Cowen | €68.04 | buy | 106.19%Upside | Reiterated | 11/02/26 | ||
| Gavin Clark-Gartner | Evercore ISI | €61.69→€70.77 | buy | 114.44%Upside | Reiterated | 08/10/26 | ||
| Yigal Nochomovitz | Citi | €63.51→€77.12 | buy | 133.69%Upside | Reiterated | 08/06/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Allison BratzelPiper Sandler | BuyReiterated€61.69 | 11/16/26 | 86.95%Upside | ||
| Anupam RamaJ.P. Morgan | BuyReiterated€81.65→€78.02 | 11/06/26 | 136.43%Upside | ||
| BuyReiterated€70.77→€60.79 | 11/05/26 | 84.20%Upside | |||
| Edward NashCanaccord Genuity | BuyReiterated€63.51→€65.32 | 11/04/26 | 97.95%Upside | ||
| Joseph PantginisH.C. Wainwright | BuyReiterated€60.79 | 11/03/26 | 84.20%Upside | ||
| Mohit BansalWells Fargo | BuyAssigned€72.58 | 11/03/26 | 119.94%Upside | ||
| Prakhar AgrawalCantor Fitzgerald | BuyReiterated | 11/03/26 | ― | ||
| Laura ChicoWedbush | BuyReiterated€68.95 | 11/03/26 | 108.94%Upside | ||
| Alex Thompson CFAStifel Nicolaus | HoldReiterated€56.25 | 11/03/26 | 70.45%Upside | ||
| Jason ZemanskyBank of America Securities | BuyReiterated€64.41→€63.51 | 11/03/26 | 92.45%Upside | ||
| Vamil DivanGuggenheim | BuyReiterated€80.75→€70.77 | 11/03/26 | 114.44%Upside | ||
| Tyler Van BurenTD Cowen | BuyReiterated€68.04 | 11/02/26 | 106.19%Upside | ||
| Gavin Clark-GartnerEvercore ISI | BuyReiterated€61.69→€70.77 | 08/10/26 | 114.44%Upside | ||
| Yigal NochomovitzCiti | BuyReiterated€63.51→€77.12 | 08/06/26 | 133.69%Upside |
Best Analysts Covering Travere Therapeutics
Copying Jason Zemansky's trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +23.50% per trade.
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 82.61% of your transactions generating a profit, with an average return of +71.79% per trade.
Copying Joseph Schwartz's trades and holding each position for 2 Years would result in 88.00% of your transactions generating a profit, with an average return of +237.40% per trade.
17R Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 2 | 7 |
| Buy | 34 | 33 | 23 | 22 | 15 |
| Hold | 1 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 35 | 35 | 25 | 26 | 23 |
In the current month, 17R has received 22 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 17R average Analyst price target in the past 3 months is 66.06.
17R Financial Forecast
17R Earnings Forecast
Next quarter’s earnings estimate for 17R is EUR 0.39 with a range of EUR 0.27 to EUR 0.55. The previous quarter’s EPS was -EUR 0.49. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
17R Sales Forecast
Next quarter’s sales forecast for 17R is EUR 220.79M with a range of EUR 194.76M to EUR 264.94M. The previous quarter’s sales results were EUR 200.32M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

